|
RVX Level II
|
3
|
Resverlogix Corp.
|
Dec 11, 2020 09:42AM
|
|
Re: Saudi
|
3
|
Resverlogix Corp.
|
Jan 09, 2021 11:54AM
|
|
Additional Exempt Distribution- 2023-05-11
|
3
|
Zenith Epigenetics
|
Jun 02, 2023 08:38AM
|
|
Re: Lower LDL-C and Increased Type 2 Diabetes Risk
|
3
|
Resverlogix Corp.
|
Jun 04, 2020 07:28AM
|
|
Re: Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
|
3
|
Resverlogix Corp.
|
Sep 28, 2022 04:41PM
|
|
Message Continuing on Clinical Trials Arena
|
3
|
Resverlogix Corp.
|
Jan 20, 2022 08:23AM
|
|
Re: RVXCF Short # drops 5.28% below 200k
|
3
|
Resverlogix Corp.
|
Mar 27, 2024 12:07PM
|
|
Re: CityNews cover
|
3
|
Resverlogix Corp.
|
Jan 31, 2022 01:01PM
|
|
Re: Report of exempt distribution
|
3
|
Resverlogix Corp.
|
Nov 10, 2020 09:22PM
|
|
Re: Level 2 Quotes this morning
|
3
|
Resverlogix Corp.
|
Jun 16, 2022 10:26AM
|
|
Re: Q4 2019 Events
|
3
|
Resverlogix Corp.
|
Oct 01, 2019 05:52PM
|
|
Re: Fair warning to everyone here....
|
3
|
Resverlogix Corp.
|
Jun 24, 2019 10:30PM
|
|
Re: Zenith-Oncology Pipeline
|
3
|
Zenith Epigenetics
|
Mar 18, 2021 05:10PM
|
|
Exempt Distribution- 2021-03-23
|
3
|
Resverlogix Corp.
|
Mar 24, 2021 02:46PM
|
|
Re: Reports of Exempt Distribution
|
3
|
Zenith Epigenetics
|
Feb 09, 2023 08:54AM
|
|
Re: No mention of efficacy again...
|
3
|
Resverlogix Corp.
|
Mar 27, 2019 04:16PM
|
|
Re: What population would our CD drug cover,...?
|
3
|
Resverlogix Corp.
|
Nov 27, 2019 09:25AM
|
|
Re: Our own BKC on the webcast
|
3
|
Resverlogix Corp.
|
Feb 15, 2021 12:51PM
|
|
October 24, 2023 How SARS-CoV-2 contributes to heart attacks and strokes
|
3
|
Resverlogix Corp.
|
Oct 29, 2023 08:36AM
|
|
Re: Apabetalone inhibits kidney damage in diabetes
|
3
|
Resverlogix Corp.
|
Aug 22, 2024 10:27AM
|
